Overview

A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

Status:
Completed

Trial end date:
2009-05-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious uveitis

Phase:

Phase 3

Details

Lead Sponsor:

Lux Biosciences, Inc.